Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation

We evaluated the possible advantages of a docetaxel (DCT) rechallenge strategy in metastatic castration-resistant prostate cancer (mCRPC) patients, also given the possible earlier positioning of this treatment option in the modern scenario. All mCRPC patients planned for DCT chemotherapy rechallenge...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Future oncology (London, England) England), 2015-11, Vol.11 (22), p.3083-3090
Hauptverfasser:	Bracarda, Sergio, Caserta, Claudia, Galli, Luca, Carlini, Paolo, Pastina, Ilaria, Sisani, Michele, Scali, Simona, Hamzaj, Alketa, Derosa, Lisa, Felici, Alessandra, Rossi, Marta, Altavilla, Amelia, Chioni, Aldo, De Angelis, Verena
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Androgens Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use Cancer therapies Chemotherapy Colorectal cancer Disease Progression docetaxel docetaxel rechallenge Endocrine therapy Follow-Up Studies Hemoglobin Humans Intention to Treat Analysis intermittent chemotherapy Kaplan-Meier Estimate Male Medical prognosis Metastasis Middle Aged Neoplasm Grading Neoplasm Metastasis Patients Prostate cancer Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - mortality Prostatic Neoplasms, Castration-Resistant - pathology Retreatment Retrospective Studies Schedules Studies Taxoids - administration & dosage Taxoids - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!